SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

28 Jul 2026 Evaluate
The total revenue for the June 2026 quarter zoomed 144.45% to Rs. 369.97 millions as compared to Rs. 151.35 millions during the year-ago period.The Net Loss for the quarter ended June 2026 is Rs. -21.03 millions as compared to Net Loss of Rs. -61.06 millions of corresponding quarter ended June 2025 Operating profit Margin for the quarter ended June 2026 improved to 5.70% as compared to -66.61% of corresponding quarter ended June 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 369.97 151.35 144.45 369.97 151.35 144.45 1129.82 1092.99 3.37
Other Income 0.23 1.69 -86.39 0.23 1.69 -86.39 2.86 13.09 -78.15
PBIDT 5.70 -66.61 -108.56 5.70 -66.61 -108.56 -150.80 -87.76 71.83
Interest 24.59 6.28 291.56 24.59 6.28 291.56 47.77 19.61 143.60
PBDT -18.89 -73.01 -74.13 -18.89 -73.01 -74.13 -198.57 -107.37 84.94
Depreciation 6.18 8.47 -27.04 6.18 8.47 -27.04 23.23 36.14 -35.72
PBT -25.07 -81.48 -69.23 -25.07 -81.48 -69.23 -221.80 -143.51 54.55
TAX -4.04 -20.42 -80.22 -4.04 -20.42 -80.22 -46.09 -40.53 13.72
Deferred Tax -4.04 -20.42 -80.22 -4.04 -20.42 -80.22 -46.09 -42.13 9.40
PAT -21.03 -61.06 -65.56 -21.03 -61.06 -65.56 -175.71 -102.98 70.63
Equity 369.84 369.84 0.00 369.84 369.84 0.00 369.84 369.84 0.00
PBIDTM(%) 1.54 -44.01 -103.50 1.54 -44.01 -103.50 -13.35 -8.03 66.23

Oxygenta Pharma Share Price

49.04 -1.35 (-2.68%)
04-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1960.00
Dr. Reddys Labs. 1160.65
Cipla 1450.00
Lupin 2376.00
Zydus Lifesciences 1118.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: